This study is being done in gastric cancer, which is cancer that starts in the stomach. It uses 68Ga-FAPI-46, a small radioactive substance given by intravenous injection so it can be seen on a PET-CT scan, a type of imaging test that shows where cancer may be in the body. The purpose of the study is to see whether this scan adds useful information during the first check-up of the cancer before treatment.

The study is for people with stomach cancer that may still be treated with the goal of cure. After the standard tests already used for staging, the participant receives the 68Ga-FAPI-46 injection and then has a PET-CT scan. The doctors then compare the new scan with the usual test results to see whether the understanding of how far the cancer has spread changes in a helpful way. This includes checking the TNM classification, which is a common way to describe the size of the tumor, whether nearby lymph nodes are involved, and whether the cancer has spread to other parts of the body.

The study also looks at whether the scan changes the planned treatment, such as surgery, chemotherapy, or radiotherapy. It is focused on how well the scan can help with the first staging of the disease, including the usual surgical look inside the abdomen when that is part of care. The study uses several forms of the same product for making the radioactive substance, including GalliaPharm and Galliad, but the imaging substance used in the scan is 68Ga-FAPI-46.